Please assess the completion status of the following clinical trial:

Trial Title: Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of familial or sporadic ALS as well as other Neurodegenerative disorders. Verification of the diagnosis will be performed by the Principal Investigator. This diagnosis can include neuro-degenerative disorders of uncertain cause, including ALS, MND, Peripheral neuropathies, Parkinson's and other progressive motor system diseases.~2. If subjects has ALS diagnosis, the date of dx should be ≤ 2 years~3. Age 18 or older.~4. Capable of providing informed consent.~5. Minimal speech impairment.~6. Ability to comply with study procedures.~7. Ability to communicate clearly if the subject wants to withdraw from the procedure at any stage.~8. MMSE ≥20~9. Female subjects of child bearing potential must engage in abstinence for the duration of the study. If a participant becomes sexually active, she must agree to using the following birth control methods:~   1. Hormonal (oral, implanted, injected, etc)~  2. Intrauterine device in place for ≥ 3 months~  3. Adequate barrier method in conjunction with spermicide~  4. Other~10. Absence of exclusion criteria.~EExclusion Criteria~1. Unable to provide informed consent~2. Significant speech impairment~3. Inability to comply with the procedures~4. Subjects with ALS diagnosis ≥ 2 years~5. Inability to communicate clearly if the subject wants to withdraw from the procedure at any stage~6. Seizures or history of seizures~7. Patients who have underwent brain surgery for any indication~8. Patients with pacemakers, cochlear implants, brain stimulators, infusion pumps, intracardiac lines, metallic clips, other implanted electronic or ferroelectric metallic devices. Dental implants are permitted~9. Inability to perform either TMS or NCS studies due to insufficient MEP or CMAP amplitude.~10. Patients with uncontrolled hypertension~11. Patients with neuro endocrine disorders~12. Patients who are withdrawn from the following drugs within 6 months:~    * Barbiturates~   * Benzodiazepines~   * Meprobamate~   * Chloral hydrate~Patients who have a recent history (within 24h) or chronic history of intake of:~* Cocaine.~* Phencyclidine Phosphate.~* Gamma-Hydroxy Butyrate.~* Amphetamines including N-methylamphetamine, 3,4-Methylenedioxymethamphetamine, 2,5-dimethoxy-4-methylamphetamine, Ephedrine, Cathinone.~  12. Substance abuse+ 13. Excessive use of alcohol # 14. MMSE ≤19 15. Female patients of child bearing potential not practicing contraception 16. Female patients who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- intervention (Type: EXPERIMENTAL): rTMS

Based on this trial design, predict the completion outcome and termination type (if applicable).